Form 4: Sana Biotechnology CEO Steve Harr Reports Stock Transactions

CEO Steve Harr reports acquisition and disposal of Sana Biotechnology stock and derivative securities, including stock options and restricted stock units.

Summary

• Steve Harr, the President and CEO of Sana Biotechnology, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• On March 7, 2025, Harr exercised options to acquire 50,000 shares of common stock at a price of $0.00.
• On March 10, 2025, Harr disposed of 12,820 shares of common stock at a price of $2.56.
• As a result of these transactions, Harr directly owns 7,876,930 shares of common stock.
• Harr also indirectly owns 682,500 shares through the Harr Family Irrevocable Trust of 2015, 167,000 shares through the Brian L Harr TTEE CCH Irrevocable Trust U/A DTD 03/25/2021 and 167,000 shares through the Brian L Harr TTEE JOH Irrevocable Trust U/A DTD 03/25/2021.
• Harr was also granted 166,667 restricted stock units on March 6, 2025, which vest in equal installments over four years.
• Additionally, Harr was granted options to purchase 750,000 shares on March 6, 2025, which vest over four years.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The granting of restricted stock units and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Negatives

• The disposal of 12,820 shares by the CEO could be interpreted negatively by some investors, although the amount is relatively small compared to his total holdings.

Risks

• The vesting of the restricted stock units and stock options is contingent upon Harr's continued service to the company, creating a potential risk if he were to leave before the vesting dates.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• Vesting schedules for these equity awards typically range from three to five years, which is consistent with the vesting schedule reported in this filing.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding the company's stock.
• The granting of equity awards to the CEO aligns his interests with those of shareholders.

Key Dates